TXMD vs. LSTA, MEIP, SYBX, INDP, ONTX, LUMO, BFRG, BIOR, VINC, and CPIX
Should you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Lisata Therapeutics (LSTA), MEI Pharma (MEIP), Synlogic (SYBX), Indaptus Therapeutics (INDP), Onconova Therapeutics (ONTX), Lumos Pharma (LUMO), Bullfrog AI (BFRG), Biora Therapeutics (BIOR), Vincerx Pharma (VINC), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.
Lisata Therapeutics (NASDAQ:LSTA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
In the previous week, Lisata Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.
Lisata Therapeutics' return on equity of -25.54% beat TherapeuticsMD's return on equity.
TherapeuticsMD has higher revenue and earnings than Lisata Therapeutics.
8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 21.6% of Lisata Therapeutics shares are held by insiders. Comparatively, 1.2% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
TherapeuticsMD received 380 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Lisata Therapeutics an outperform vote while only 62.66% of users gave TherapeuticsMD an outperform vote.
Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 425.73%. Given TherapeuticsMD's stronger consensus rating and higher probable upside, research analysts plainly believe Lisata Therapeutics is more favorable than TherapeuticsMD.
Lisata Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Summary
Lisata Therapeutics beats TherapeuticsMD on 7 of the 13 factors compared between the two stocks.
Get TherapeuticsMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TherapeuticsMD Competitors List
Related Companies and Tools
